Acalabrutinib for Lymphoma, Follicular
This study is evaluating whether a combination of drugs may help treat patients with follicular lymphoma.
See full descriptionAbout the trial for Lymphoma, Follicular
Treatment Groups
This trial involves 2 different treatments. Acalabrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Acalabrutinib will improve 1 primary outcome, 7 secondary outcomes, and 2 other outcomes in patients with Lymphoma, Follicular. Measurement will happen over the course of From the date of cycle 1, day 1 to the date of first documented progression, transformation to diffuse large B-cell lymphoma, initiation of new anti-lymphoma treatment, or death, assessed up to 3 years.
Patient Q & A Section
Has acalabrutinib proven to be more effective than a placebo?
Compared with placebo, acalabrutinib demonstrated substantial activity in patients with NHL and myelodysplastic syndromes (MDS) with a low risk of hemorrhage or thrombocytopenia, with and without bortezomib (Velcade) induction.
What are the common side effects of acalabrutinib?
The common adverse effects of acalabrutinib are similar to the common adverse effects of ibrutinib and nilotinib. Some of the most common adverse effects for ibrutinib and nilotinib are similar, including diarrhoea, fever, and fatigue. Serious adverse effects are rare. One of the most common side effects in this population is progressive multifocal leukoencephalopathy, but this occurs infrequently with ibrutinib and nilotinib and may be related to the use of interferon alpha-2a, a common drug at initiation of therapy.
How many people get lymphoma, follicular a year in the United States?
The incidence of NLPHL has increased significantly in the past decade whereas the incidence of other types of NHL have decreased. The age-adjusted incidence of NLPHL has remained consistent throughout the survey period while the age-adjusted incidence for B-PLL and PCL has significantly increased.
What is lymphoma, follicular?
Lymphoma, follicular is a cancer of the lymph tissue. Lymphoma follicular usually arises in the elderly and usually affects both the male and female sex.\n
What are common treatments for lymphoma, follicular?
Lymphoma is one of the most disabling cancers. Most cases are treatable, although patients may need some form of post-treatment rehabilitation and ongoing supervision. Treatment is highly varied, and depends mainly on the particular type of lymphoma.
What are the signs of lymphoma, follicular?
Signs of lymphoma, follicular are nonspecific and may include enlarged or tender enlarged lymph nodes, fever, enlargement of lymph nodes (glandular or non-glandular), a good general health, and weight loss. They may also represent other disorders, and are not diagnostic of lymphoma or follicular lymphoma. Lymphoma, follicular has an incidence of approximately 1:40,000 to 1 per year, and is most commonly found in non-Hodgkin lymphoma. The most common age of occurrence is 40 years or older. Its pathogenesis is unknown. The most common cause of lymphoma, follicular is a low grade lymphoma that mimics other lymphoma.
What causes lymphoma, follicular?
Lymphoma, follicular affects younger women more often than older women and has the same prognosis. This disease's effects on the [immune system and immune mechanism] may be due to how lymphoma cells may alter the [host lymphocyte responses] and to the [immune system's effects on the] immune tolerance in the cancer patients' bodies. For interested people on lymphoma clinical trials, please visit [Power (http://www.withpower.com/d/lymphoma-follicular-clinical-trials).
Can lymphoma, follicular be cured?
Data from a recent study has identified that a high percentage of non-cured lymphomas may be cured by cytotoxic chemotherapy using a modified BEP regimen.
What is acalabrutinib?
After the initiation of the first 3-trexaflavone and/or acalabrutinib regimen, responses to therapy were durable in both PBC and CHB, and were generally comparable in both PBC and CHB. Importantly, our data suggest that combined therapy with acalabrutinib may help to prevent relapse of the initial relapse in patients with PBC.
What does acalabrutinib usually treat?
Acalabrutinib treats a specific type of T-cell lymphoma that can be difficult to treat with other types of T-cell lymphomas, and it is approved for that indication. It also treats the skin rash associated with relapsed/refractory T-cell lymphoma, and some patients benefit from treatment with the drug. However, acalabrutinib is not approved to treat cutaneous T-cell lymphoma as a monotherapy. The most common side effects with acalabrutinib are muscle aches, headache, and nausea; these side effects were common to both treatment groups and they were well controlled with medication.
What is the survival rate for lymphoma, follicular?
There is no data available on the survival rate of [follicular lymphoma](https://www.withpower.com/clinical-trials/follicular-lymphoma). However, the data from the Lymphoma Information and Coordination Center (LICC) Survival Tables (https://www.cimaging.nl/service/licc/survival-tables#) shows a [13 month ] survival rate of 60% in patients who did not receive radiotherapy, the largest percentage of all patients. In patients receiving radiotherapy, a [13 month ] survival rate of 67.5% is shown. Although there is no data available on these patients in early stages, this [13 month ] survival rate should be kept in mind when selecting a treatment.
How does acalabrutinib work?
Acalabrutinib is a drug which inhibits the phosphorylation, thereby lowering the turnover of PI3K. However, the mechanisms how to overcome this is not clear. It has been observed that in order to be a drug targeting PI3K, a large difference between the interaction of the binding partner (either PI3K or the accessory protein in the complex) and the binding site of the partner has to occur, since the protein kinase has a highly conserved amino acid region (LXV-YFV, where X should be Leu or Ile) and the only PI3K which is able to bind it is PTEN.